Trial Profile
A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2021
Price :
$35
*
At a glance
- Drugs Felcisetrag (Primary)
- Indications Diabetic gastroparesis; Gastroparesis
- Focus Therapeutic Use
- Sponsors Takeda
- 12 Mar 2021 Results published in the Alimentary Pharmacology and Therapeutics.
- 19 May 2020 Primary endpoint (Half time (T1/2) of Gastric Emptying of Solids) has been met, according to results published in Gasteroenterology in conjunction with Digestive Disease Week 2020
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020